TY - JOUR
T1 - Evaluation of the Immunogenicity of Oil-Based Mycoplasma gallisepticum Killed Vaccine in
Broiler Chickens Experimentally Prepared from Local Isolate of Bangladesh
AU - Rahman, Md. Masudur AU - Noor, Monira AU - Islam Basit, Md. Shamsul AU - Ahmed, Sultan AU - Mahbobur Rajib, Dewan Muhammad AU - Das, Shobhan
JO - Journal of Animal and Veterinary Advances
VL - 19
IS - 8
SP - 107
EP - 112
PY - 2020
DA - 2001/08/19
SN - 1680-5593
DO - javaa.2020.107.112
UR - https://makhillpublications.co/view-article.php?doi=javaa.2020.107.112
KW - CRD
KW -Mycoplasma gallisepticum
KW -PCR
KW -serological evaluation
KW -vaccine candidate
AB - The study was aimed to evaluate the
immunogenicity of experimentally prepared Mycoplasma
gallisepticum killed vaccine in broiler chickens under
field conditions in Bangladesh. Isolation and
identification of Mycoplasma gallisepticum was
performed by cultural, biochemical and PCR assays.
Oil-based formalin killed mycoplasma vaccine was
prepared from one field isolate. To evaluate the
immunogenicity of the vaccine, day-old broiler chicks
(n = 60) were randomly divided into three equal groups
namely Group-A (non-vaccinated control), Group-B (trial
vaccine) and Group-C (imported vaccine).
Immunogenicity of locally prepared trial vaccine and
imported vaccine was evaluated by ELISA. In chickens of
control group (Group-A), the mean anti-MG ELISA
antibody titer gradually decreased whereas that of trial
vaccine (Group-B) and imported vaccine (Group-C)
increased gradually after 15 days post-vaccination. The
oil-adjuvant MG trial vaccine conferred anti-MG-ELISA
antibodies in broilers after 15 days of vaccination that
reached to the maximum level (2213.75±3.126) at 45 days
post priming which is comparable with the imported
vaccine (2121.75±3.431). The maternal antibody in chicks
did not interfere with the trial and imported vaccines as
both were killed vaccines. We conclude that the prepared
vaccine candidate might be promising to control
mycoplasmosis in Bangladesh. However, the protective
efficacy of the vaccine needs to be evaluated before
recommending the vaccine finally.
ER -